search

Active clinical trials for "Esophageal Neoplasms"

Results 461-470 of 1263

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal...

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma5 more

This phase 2 trial evaluatesteh benefit of epacadostat plus pembrolizumab in combination to treat patients with gastroesophageal junction or gastric cancer that has spread to other parts of the body and cannot be removed by surgery. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving epacadostat and pembrolizumab may work better in treating patients with gastroesophageal junction or gastric cancer.

Completed45 enrollment criteria

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric CancerGastroesophageal Junction Adenocarcinoma

This is a single-arm clinical trial.The purpose of this study is to evaluate the efficacy and safety of Raltitrexed and Paclitaxel as second-line chemotherapy for patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma .The primary endpoint of this study is objective response rate.The secondary endpoint of this study is safety,progression-free survival and overall survival.

Completed15 enrollment criteria

PDL-1 Targeting in Resectable Oesophageal Cancer

Esophageal CancerStage II1 more

Objectives The primary objective of this study is to assess the feasibility of preoperative treatment with atezolizumab combined with preoperative chemoradiation (carboplatin, paclitaxel and radiation) in terms of completion of treatment with atezolizumab.

Completed32 enrollment criteria

Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma...

Esophageal Carcinoma

The purpose of this study is to evaluate the safety, tolerance and efficacy of Liposomal Paclitaxel With Nedaplatin as First-line in patients with Advanced or Recurrent Esophageal Carcinoma

Completed15 enrollment criteria

Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer

Metastatic Esophageal Cancer

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced esophageal cancer.

Completed7 enrollment criteria

The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I

Lung NeoplasmsEsophageal Neoplasms1 more

Stage I of the Thoracic-POISE study will pilot-test a broad-based, multi-agent integrative care intervention delivered by naturopathic doctors in conjunction with standard surgical and oncologic care of people with thoracic cancer.

Completed10 enrollment criteria

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients...

Gastroesophageal Junction AdenocarcinomaMalignant Neoplasm of the Cervical Esophagus6 more

This phase I trial studies the side effects and best dose of ganetespib when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-III esophageal cancer. Ganetespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving ganetespib in combination with paclitaxel, carboplatin, and radiation therapy may be a better treatment for patients with esophageal cancer.

Completed35 enrollment criteria

PCA062 in pCAD-positive Tumors.

Triple Negative Breast CancerHead & Neck Cancer1 more

A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.

Completed27 enrollment criteria

2D-radiotherapy in Palliation of Advanced Esophageal Cancer

Palliative Care

The study wants to define the efficacy of a short course 2D-radiation therapy in patients with symptomatic advanced esophageal cancer.

Completed5 enrollment criteria

M1231 in Participants With Solid Tumors

Metastatic Solid TumorsEsophageal Cancer1 more

This study is to establish a safe and tolerable dose and to investigate pharmacokinetics and the first clinical efficacy signals of M1231 as a single agent in participants with solid tumors (Part 1) and with metastatic Non-small Cell Lung Cancer (NSCLC) and esophageal squamous cell carcinoma (Part 2). Dose escalation will be followed by the dose expansion once the maximum tolerated dose (MTD) or recommended dose for Expansion (RDE) has been defined.

Completed20 enrollment criteria
1...464748...127

Need Help? Contact our team!


We'll reach out to this number within 24 hrs